Direct-to-Patient (DTP) refers to a clinical trial approach where study medications and supplies are delivered directly to participants’ homes. This model eliminates the need for patients to visit clinical sites frequently, improving convenience and potentially increasing retention rates in clinical studies.
DTP services can include the shipment of investigational products, collection of biological samples, and even the administration of treatments by healthcare professionals in the patient’s home. This approach has gained popularity, especially in the context of rare disease studies and during global health crises that limit patient mobility.
Direct-to-Patient (DTP) is crucial in clinical research as it addresses key challenges in patient recruitment and retention. By reducing the burden of travel and site visits, DTP models can significantly improve participant experience and compliance, leading to more robust and reliable study data.
Furthermore, DTP approaches expand the geographical reach of clinical trials, allowing researchers to include patients from diverse locations who might otherwise be unable to participate. This increased accessibility can accelerate study timelines, enhance the representativeness of study populations, and potentially lead to more generalizable results.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant